glp-1 antagonist mechanism of action Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Mechanisms by which GLP-1 agonists

Fishes2023, 8(1), 26

Tirzepatide is actively studied in research on dual incretin receptor pharmacology, adipose tissue biology, beta-cell preservation, NASH resolution, obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), and polycystic kidney disease

Eloralintide acts like amylin, because it is a selective amylin-agonist, she continued

Public Opinion on Medicare Coverage of GLP-1s for Weight Loss While some Medicare drug plans cover the cost of some GLP-1s such as Ozempic or Wegovy when prescribed to treat diabetes or prevent heart attacks or strokes for adults with heart disease, Medicare is currently prohibited by law from covering drugs when prescribed for weight loss for more information, see KFFs issue brief on Medicare coverage of GLP-1s

For selected patients, yes